Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

PaperCitations, authors & open-access status

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 126 citations, 2018 year and closed oa status.

126
Citations
2018
Year
closed
OA Status

Related on ScholarIQ

Stacie Hudgens
Author
The Lancet Oncology
Journal
PARP inhibition in cancer therapy
Topic
PARP inhibition in cancer therapy
Topic
Ovarian cancer diagnosis and treatment
Topic
Advanced Breast Cancer Therapies
Topic
470M+ articles · free account